• Users Online: 2095
  • Print this page
  • Email this page

 Table of Contents    
Year : 2013  |  Volume : 57  |  Issue : 2  |  Page : 137-144  

The role of melatonin in anaesthesia and critical care

Department of Anaesthesiology, Karnataka Institute of Medical Sciences, Hubli, Karnataka, India

Date of Web Publication15-May-2013

Correspondence Address:
Madhuri S Kurdi
Department of Anaesthesiology, Karnataka Institute of Medical Sciences, Hubli, Karnataka
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0019-5049.111837

Rights and Permissions

Melatonin is a neurohormone secreted by the pineal gland. It is widely present in both plant and animal sources. In several countries, it is sold over the counter as tablets and as food supplement or additive. Currently, it is most often used to prevent jet lag and to induce sleep. It has been and is being used in several clinical trials with different therapeutic approaches. It has sedative, analgesic, anti-inflammatory, anti-oxidative and chronobiotic effects. In the present review, the potential therapeutic benefits of melatonin in anaesthesia and critical care are presented. This article aims to review the physiological properties of melatonin and how these could prove useful for several clinical applications in perioperative management, critical care and pain medicine. The topic was handsearched from textbooks and journals and electronically from PubMed, and Google scholar using text words.

Keywords: Anaesthesia, antioxidant, chronic pain, critical care, hypnosis, melatonin, oral pre-medication, perioperative role, sepsis management

How to cite this article:
Kurdi MS, Patel T. The role of melatonin in anaesthesia and critical care. Indian J Anaesth 2013;57:137-44

How to cite this URL:
Kurdi MS, Patel T. The role of melatonin in anaesthesia and critical care. Indian J Anaesth [serial online] 2013 [cited 2021 May 8];57:137-44. Available from: https://www.ijaweb.org/text.asp?2013/57/2/137/111837

   Introduction Top

Melatonin, once labelled as a master hormone, is a natural substance present in all major taxa of organisms. [1],[2],[3] It is produced mainly in the pineal gland of all mammals and vertebrates and its secretion is high during night time and low during day time. [2],[4],[5],[6] Melatonin is also synthesized in a number of other organs and peripheral tissues from tryptophan. [7],[8],[9] Melatonin is a natural constituent of food. Foods rich in melatonin include cherries, rice, beet, cucumber, tomatoes, human milk, yeast, bananas, wine and beer. [10] Melatonin has a spectrum of important properties and plays several important physiological roles, many of which can have important clinical applications. Some experimental studies and clinical trials are providing the basis for future clinical applications of melatonin of use to the anaesthesiologist. Keeping this in mind, we conducted a literature search to review the various physiological roles of melatonin and explore its various potential uses in anaesthesia, critical care and pain medicine.

   Physiological Roles of Melatonin Useful to the Anaesthesiologist Top

Sleep induction and maintenance

Melatonin is best known by medical professionals and laypersons for its hypnotic actions. Several studies have showed the importance of melatonin both for the initiation and maintenance of sleep. [11] The hypnotic effects of melatonin are considered as an integral component of its physiological role. [12] It has been reported to improve sleep onset, duration and quality when administered to healthy volunteers, suggesting a pharmacological hypnotic effect. [13] Melatonin is a natural hypnotic and exerts its hypnotic effects through the activation of the MT1 and MT2 melatonin receptors. [14] The suppression of neuronal activity by melatonin is one of the possible mechanisms by which it contributes to the regulation of sleep. [15] There is evidence to suggest that the central effects of melatonin involve, at least in part, facilitation of GABAergic transmission by modulating the GABA receptor. [16] In human beings, peak values of melatonin concentration seen in the evening are associated with the lowest point in rhythms of core body temperature, alertness, mental performance and many metabolic functions and with maximum sleep propensity. [17] Melatonin and its analogs are different from benzodiazepines and their derivatives in that they exert a promoting effect on sleep by amplifying day/night differences in alertness and sleep quality and displaying a modest sleep inducing effect, quite mild as compared to that seen with benzodiazepines. [18] Moreover, melatonin produces no hangover effects on the day following its intake. Melatonin and its analogs lack negative effects like addiction, dependence as compared to benzodiazepines. [11]

Analgesic effects

In experimental studies, melatonin shows potent analgesic effects in a dose-dependent manner. [19] The physiological mechanism underlying the analgesic effect of melatonin has not been clarified. [20],[21] The effects may be linked to Gi-coupled melatonin receptors, to Gi-coupled opioid μ receptors or GABA-B receptors. The exact site of action of melatonin to induce anti-nociception is not clear. [22] Possibly, it augments GABA-ergic systems and morphine anti-nociception, enhancing GABA-induced currents and inhibiting glycine effects. [23] Melatonin may enhance the levels of β-endorphins and the anti-nociception induced by delta opioid receptor agonists and could activate MT 2 melatonin receptors in the dorsal horn of the spinal cord. [24],[25] Melatonin is involved in the modulation of nociceptive transmission. Intrathecally administered melatonin is active against the formalin and thermal-induced nociception at the spinal level in rats. [26]

Anti-inflammatory and immunological effects

Melatonin has immune-enhancing and anti-corticoid function. It modulates the activity of the pineal and pituitary/adrenal axis and the peripheral actions of corticoids. [1] It releases vasotocin that lowers corticoid levels. [1] Other possible mechanisms for melatonin's anti-inflammatory effects include inhibition of COX-2 and iNOS enzymes, activation of NF-kB and inhibition of neutrophil infiltration. [27] It enhances thymocyte proliferation and IL-2 production. [28] Melatonin exhibits immunomodulatory properties and modulatory influence on the NO synthetase (NOS) and cytokine production in inflammatory and oncostatic processes. [29] It has been reported as effective in combating various bacterial and viral infections. [30]

Anti-oxidative effects

Melatonin is a powerful antioxidant. [31],[32] Melatonin antagonises oxidative stress both in a direct and in an indirect way. [33],[34],[35] It prevents free radical-induced damage and increases the activity of several antioxidant enzymes like glutathione-S transferase, glutathione reductase and catalase. [36]

Chronobiotic property

Melatonin is an important regulator of the body circadian rhythm. [37],[38] The circadian rhythm of pineal melatonin release is highly synchronised with the habitual hours of sleep and the daily onset of melatonin secretion is well correlated with the onset of the steepest increase in nocturnal sleepiness. [11] Anaesthesia in conjunction with surgery acutely disturbs the normal circadian rhythm of melatonin by delaying the onset of nocturnal melatonin secretion. [16],[39]

Antihypertensive effect

Melatonin has a mild hypotensive effect. The mechanism of action on the circulation is complex and unclear. Melatonin may bind to specific melatonin receptors in the blood vessels, interfering with the vascular response to catecholamines. [24],[40] It may interfere with the peripheral and central autonomic system, causing a reduction in adrenergic outflow and catecholamine levels. [16],[41] It may induce relaxation of the smooth muscle of the arterial walls by increasing nitric oxide availability. [16],[42] Night time melatonin supplementation reduced nocturnal blood pressure in otherwise untreated hypertensive men and in non-dipping hypertensive women in some studies. [27]

Ocular hypotensive effect

Melatonin has ocular hypotensive effect. The mechanism is not clear. It may have a complex, albeit undefined role in aqueous humour formation, since melatonin receptors (M2 and M3) were recognized in the ciliary body tissues in animals. [22],[43],[44]

   Potential Clinical Applications of Melatonin in Anaesthesia and Critical Care Top

Pre-medication before surgery

Melatonin possesses sedative, hypnotic, analgesic, anti-inflammatory, anti-oxidative and chronobiotic properties that distinguish it as an attractive alternative pre-medicant. [45]

In adult patients

A systematic review of literature concerning the perioperative use of melatonin in adults provided evidence that melatonin pre-medication is effective in ameliorating pre-operative anxiety, but its analgesic effects in the perioperative period remain controversial. [45] Pre-medication with 0.05, 0.1 or 0.2 mg/kg sublingual/oral melatonin is associated with pre-operative anxiolysis and sedation without impairment of orientation, psychomotor skills or impact on quality of recovery. [46],[47] Ismail and Mowafi have found in a study that 10 mg oral melatonin pre-medication for patients 90 minutes before cataract surgery under topical anaesthesia provided anxiolytic effects, enhanced analgesia and decreased intraocular pressure with good operating conditions. [24] Compared to midazolam, pre-operative melatonin has a similar anxiolytic efficacy yet with less psychomotor impairment and fewer side effects. [18] Melatonin is an effective pre-medicant before IVRA, since a single oral dose of melatonin 10 mg before IVRA reduced patient anxiety, decreased tourniquet-related pain and improved perioperative analgesia. [48]

Rana Altaf Ahmed et al. in a study found that sublingual melatonin 0.5 mg/kg pre-medication in adults undergoing cataract surgery under local anaesthesia significantly decreased anxiety levels with no amnesia, sleep and next day hangover effects. [18] In a study by Ionescu D et al., 3 mg oral melatonin was used successfully as pre-medication for laparoscopic cholecystectomy and at this dose, it produced anxiolysis. [49]

In a study on 75 women, Naguib and Samarkandi found that patients who received pre-medication with 5 mg melatonin 100 minutes pre-operatively had a significant decrease in anxiety levels and increase in levels of sedation before operation with no amnesia for pre-operative events. [50]

Nevertheless, in a study by Capuzzo et al., oral melatonin 10 mg pre-medication did not significantly reduce anxiety in elderly patients undergoing elective surgery. [51]

In children

The use of melatonin, especially in children younger than 3 years, has decreased significantly the number of youngsters undergoing GA for diagnostic exploration like brainstem audiometry. [52] Pre-procedure 10 mg melatonin 30 minutes before MRI examination improved the success rate of procedure in sleep-deprived children. However, in another study, in children pre-treated with melatonin 3-6 mg and undergoing MRI examination, melatonin did not contribute to sedation. [53]

Clinical trials with melatonin as a pre-medication agent in anxious children under nitrous oxide-oxygen sedation for dental treatment have shown good results, but so far, only limited data are available. [54] Few clinical studies have shown that melatonin is as effective as midazolam in reducing pre-operative anxiety in children and is associated with a more rapid recovery, a reduced incidence of emergence delirium and decreased incidence of sleep disturbances 2 weeks after surgery when compared to midazolam. [46],[55] Currently, there is no consensus on the appropriate dose of melatonin for sedation in children. Melatonin dosing for children is reported to be between 0.3 and 20 mg. [55]

Thus, in view of its many benefits as a pre-medicant, patients on melatonin supplements should continue taking them perioperatively. [56]

Hypnosis and analgesia as an anaesthetic agent/adjuvant

The hypnotic, anti-nociceptive and anticonvulsant properties of melatonin endow melatonin with the profile of a novel hypnotic anaesthetic agent. Anton-Tay and co-workers were the first to demonstrate clearly that orally administered 0.2 mg/kg melatonin produced loss of consciousness in human beings accompanied by a pattern of EEG activity similar to that seen during intravenous and volatile anaesthetic-induced loss of consciousness. [16] It significantly reduced the induction dose of propofol and thiopental. [16] Some researchers have found that oral melatonin 3 or 5 mg as pre-medication reduced the induction dose of propofol without prolongation of the post-operative recovery room stay. [57]

Orally administered melatonin has been shown to potentiate the anaesthetic effects of thiopental and ketamine and ether in rats. [58] Intra-peritoneal injection of 100 mg/kg melatonin significantly reduced MAC for isoflurane in rats by 24% when compared to control. [16] Melatonin and melatonin analogs possess hypnotic properties when injected intravenously, comparable to the properties of propofol and thiopental including the EEG effects with the additional advantage of providing analgesia, at least in animal studies. [59],[60]

However, in a study on women undergoing hysteroscopy on day care basis, sublingual melatonin 9 mg as pre-medication 30 minutes before induction did not enhance the inhalation induction of anaesthesia with sevoflurane. [61]

The IV administration of 2-bromomelatonin can exert hypnotic effects and anti-nocifensive effects with a profile similar to that induced by propofol in that it exerts a rapid onset and short duration of action. [62]

Melatonin on its own does not seem to possess sufficient efficacy to warrant consideration as a general anaesthetic, but it may be used as a general anaesthetic adjuvant. [63]

Miscellaneous peri-operative uses

In patients with hypertension

In a study by Ismail and Mowafi, mean arterial pressure decreased after melatonin pre-medication and extended to the early post-operative period. This mild hypotensive effect of melatonin may be beneficial in elderly patients, particularly those at cardiovascular risk. [24]

For neuroprotection and as an anticonvulsant

Melatonin by virtue of its antioxidant properties protects against oxidative stress, prevents neuronal damage associated with epilepsy, has putative neuroprotective effects and can be used as an anticonvulsant. [35]

To reduce intraocular pressure

10 mg oral melatonin 90 minutes before cataract surgery under topical anaesthesia has been reported to decrease intraocular pressure and produced good operating conditions. [24]

To improve surgical outcomes

Melatonin in surgical neonates resulted in improvement of clinical outcomes by virtue of its ability to reduce oxidative stress related to surgical procedures. [64] A pre-operative single dose of melatonin 50 mg/kg body weight dissolved in 250 ml of milk and administered through gastric tube after intubation for general anaesthesia was effectively absorbed, safe and well tolerated and decreased inflammatory changes after major liver resection. [65] Melatonin has been shown to be effective in preventing post-surgical adhesion formation in rat uterine horn adhesion model. [66]

Post-operative use of melatonin

Anxiolytic and analgesic effects of melatonin may improve the control of post-operative pain by controlling the higher anxiety that accompanies surgical interventions. [67] Caumo et al. found that 5 mg oral melatonin, the night before and 1 hour before surgery in patients undergoing abdominal hysterectomy, decreased pain and anxiety during the first 24 hours after surgery. Also, they had better recovery of the rhythmicity perceptual in the first post-operative week after discharge. [22]

In a clinical study, it was found that a pre-emptive oral dose of 6 mg of melatonin reduced the pain scores and pethidine requirements in the first post-operative 24 hours in patients undergoing abdominal surgery. [67] In another study, pre-operative oral melatonin 6 mg, the night before and 1 hour before surgery, decreased pain scores and tramadol consumption and enhanced sleep quality and sedation scores during the post-operative period in patients undergoing elective prostatectomy. [68]

Disrupted sleep wake cycle after surgery leads to post-operative delirium. Melatonin can regulate this cycle which is disrupted after surgery. [69] The pre-operative administration of melatonin may accelerate the resynchronization of circadian rhythms in the post-operative period, suggesting better recovery quality. This could be a consequence of melatonin's effects on pain and anxiety which enhance rhythmicity disruption in stressful situations such as surgeries. [22] Clinical trials on the effect of melatonin on delirium in hip fracture patients are going on. Melatonin has been used successfully to treat and prevent post-operative delirium. [70]

In a study on pre-medication in children, oral melatonin 0.1 mg/kg, oral dexmedetomidine 2.5 μg/kg and oral midazolam 0.5 mg/kg were equally efficient in reducing the incidence of emergence agitation in children after sevoflurane anaesthesia. [71] In a study by Kain ZN et al., children who received pre-operative oral melatonin 0.05 mg/kg developed less emergence delirium compared with those who received oral midazolam (0.5 mg/kg) and the effects were dose related. [72]

However, in a study by Gogenur et al., on patients undergoing laparoscopic cholecystectomy, oral 5 mg melatonin for three nights after surgery did not improve sleep quality, fatigue or increased well being. Nevertheless, it decreased sleep latency on the first post-operative night. [73]

In intensive care

In sepsis

The anti-oxidative properties of melatonin are being investigated for use in sepsis and reperfusion injuries. [56]

Melatonin 3 mg/kg IV 3 hourly in rats with peritonitis-induced septic shock with multi organ dysfunction syndrome (MODS) significantly attenuated hyporeactivity to nor-epinephrine and delayed hypotension, reduced plasma index of hepatic and renal dysfunction, reduced infiltration of polymorphonuclear neutrophils in the lung and liver tissue and promoted survival rate at 18 hours to two fold. [74] Melatonin has well-documented protective effects against the symptoms of severe sepsis/shock in both animals and in human beings; its use for this condition significantly improves survival. Melatonin clearly arrests cellular damage and prevents multi organ failure, circulatory failure and mitochondrial damage in experimental sepsis, and reduces lipid peroxidation, indices of inflammation and mortality in septic human newborns. [30],[75] Melatonin has been found to be beneficial in treating premature infants suffering from severe respiratory distress syndrome and septic shock. [34] It has been found to be effective in combating various bacterial and viral infections. [30],[76] In a study, 20 mg oral melatonin in two divided doses of 10 mg each, with a 1-hour interval, improved the clinical outcome of septic newborns. [77]

However, Bagci et al. stated that further investigations are needed to identify whether treatment with melatonin may have beneficial effects in paediatric intensive care unit patients with sepsis/septic shock. [78] Melatonin has been proposed to be used as a pharmacological support in burn patients where it reduced oxidative damage. [79]

For protection against organ injury

Melatonin has been found to be protective against glycerol-induced renal failure in rats. It was also found to be protective against lung injury in an animal study. This is because of its antioxidant effects. [1],[80]

Sleep disorders in critically ill patients

The reduction in plasma melatonin levels and loss of circadian rhythm observed in critically ill patients receiving mechanical ventilation may contribute to an irregular sleep wake pattern and sleep disturbances in them with compromise of nocturnal sleep time. Oral melatonin at 9 pm every night was associated with a 1 hour increase in nocturnal sleep and increased nocturnal sleep efficiency. [81]

More clinical evidence is required to confirm the potential benefits of melatonin supplementation before it can be routinely used in the critically ill patient. [82]

Treatment and prevention of stress-induced gastric ulcers

Melatonin is generated in the GIT and serves as a local antioxidant and protective factor. [28] Melatonin has ulcer-healing and gastroprotective effects. This involves hyperaemia at ulcer margin and numerous mechanisms including activation of brain gut axis, sensory afferent nerves and certain gut hormones, especially gastrin. [29]

Pain management

The melatonin dose with analgesic potential is undefined. [24] Melatonin has been associated with the relief of pain in patients with extensive tissue injuries. [22]

Melatonin has analgesic benefits in patients with chronic pain - fibromyalgia, inflammatory bowel syndrome, migraine. Disturbances in melatonin secretion have been proposed to be part of the pathophysiology leading to fibromyalgia. [19] Melatonin when given in doses of 3 mg orally for 4 weeks, 30 minutes before sleeping time, significantly improved sleep quality and resulted in significantly fewer painful trigger points. [19],[83] Melatonin alleviates abdominal pain in patients with inflammatory bowel syndrome (IBS). [84] Melatonin 3 mg for 2 weeks attenuated abdominal pain and bloating and reduced rectal pain sensitivity in patients with IBS. [84] The urinary melatonin concentration was found to be low in subjects suffering from migraine and trials have shown that melatonin may have both therapeutic and prophylactic benefit in patients suffering from migraine headaches. [85],[86]

Melatonin reduces tactile allodynia in neuropathic rats after intrathecal and oral administration. [87]

   Safety of Melatonin Top

Melatonin is reported to have a high and an excellent safety profile. [45],[88] It is usually remarkably well-tolerated. Very high doses (300 mg/day) were given orally for up to 2 years and found to be safe. [89] Sugden reported a potential for motor incoordination when using melatonin in high doses in experimental studies. [83],[90] The reported side effects of melatonin include 4% fatigue and 3% nausea. Doses of melatonin as great as 20 mg were administered to children without producing adverse side effects apart from sedation. [55] Dizziness, headache and irritability may be other adverse effects seen with very high doses. [13] The interaction of melatonin with other drugs has not been systematically evaluated. [1],[13]

   Availability of Exogenous Melatonin Top

Exogenous melatonin is available in a range of preparations for sublingual and oral administration. [56] It is available over the counter in several countries including USA and India. [4] It is widely available as a nutritional adjunct and over-the-counter supplement marketed by different companies. These supplements may contain additional vitamins. [1]

Although melatonin has potential therapeutic value in operative and critical care settings, it has not been approved by the FDA as a therapeutic drug. [16]

Melatonin analogs have been synthesized. [4] There are two melatonin agonists on the market today, ramelteon and agomelatine. [4],[11] Ramelteon has been approved by the US FDA for long-term use for the treatment of insomnia. [4],[11] Additionally, two melatonin agonists, Tasimelteon and TIK-301, have been granted orphan drug designation and are going through clinical trials in the USA. [11] The main advantage of melatonin analogs is their good safety profile because of specificity for either or both of the two principal melatonin membrane receptors: MT 1 and MT 2 . [4] Slow release forms of melatonin are being developed. [11]

   Conclusions Top

Melatonin by virtue of its multiple functions has the potential to take a place in the anaesthetic drug armamentarium, because it can be an attractive option for pre-medication as an anxiolytic and sedative, for the induction of general anaesthesia as a hypnotic or as an induction adjuvant and peri-operatively for analgesia, reducing inflammation and for providing favourable operative conditions. Melatonin can also be used post-operatively to restore sleep rhythm and prevent delirium, in the intensive care unit for sepsis management and neuroprotection and in the pain clinic for the management of some painful conditions. The surgical and ICU patients may benefit from an evening meal that is rich in melatonin. Data support the notion that melatonin, or one of its analogs, might find use as an anaesthetic agent or adjuvant. As anaesthesiologists, intensivists and pain physicians, we may benefit multimodally from melatonin. Well-designed randomised controlled trials are warranted to further investigate the use of melatonin in anaesthesia, intensive care and pain medicine.

   References Top

1.Malhotra S, Sawhney G, Pandhi P. The therapeutic potential of melatonin: A review of the science. Med Gen Med 2004;6:46.  Back to cited text no. 1
2.Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med Rev 2005;9:11-24.  Back to cited text no. 2
3.Pfeffer M, Kuhn R, Krug L, Korf HW, Stehle JH. Rhythmic variation in beta-adrenergic receptor m RNA levels in the rat pineal gland: Circadian and developmental regulation. Eur J Neurosci 1998;10:2896-904.  Back to cited text no. 3
4.Arendt J, Rajaratnam Shantha MW. Melatonin and its agonists: An update. Br J Psychiatry 2008;193:267-9.  Back to cited text no. 4
5.Arendt J. Melatonin: Characteristics, concerns and prospects. J Biol Rhythms 2005;20:291-303.  Back to cited text no. 5
6.Wehr TA, Duncan WC Jr, Sher L, Aeschbach D, Schwartz PJ, Turner EH, et al. A circadian signal of change of season in patients with seasonal affective disorder. Arch Gen Psychiatry 2001;58:1108-14.  Back to cited text no. 6
7.Brown GM, Cardinali DP, Pandi-Perumal SR. Ramelteon: A review of its therapeutic potential in sleep disorders. Adv Ther 2009;26:613-26.  Back to cited text no. 7
8.Klein DC. Arylalkylamine N- acetyltransferase: The timezyme. J Biol Chem 2007;282:4233-7.  Back to cited text no. 8
9.Tricoire H, Locatelli A, Chemineau P, Malpaux B. Melatonin enters the cerebrospinal fluid through the pineal recess. Endocrinology 2002;143:84-90.  Back to cited text no. 9
10.Dubbels R, Reiter RJ, Klenke E, Goebel A, Schnakenberg E, Ehlers C, et al. Melatonin in edible plants identified by radioimmunoassay and by high performance liquid chromatography-mass spectrometry. J Pineal Res 1995;18:28-31.  Back to cited text no. 10
11.Cardinali DP, Srinivasan V, Brzezinski A, Brown GM. Melatonin and its analogs in insomnia and depression. J Pineal Res 2011;52:365-75.  Back to cited text no. 11
12.Naguib M. The effects of melatonin premedication on propofol and thiopental induction dose-response curves: A prospective, randomized, double-blind study. Anesth Analg 2006;103:1448-52.  Back to cited text no. 12
13.Dennely CE, Sourouivs CT. Dietary supplements and herbal medications. In: Katzung BG, Masters SB, Trevor AJ, editors. Basic and Clinical Pharmacology, 11 th ed. Newyork: The McGraw Hill Companies; 2009.p. 1123-4.  Back to cited text no. 13
14.Zisapel N. Sleep and sleep disturbances: Biological basis and clinical applications. Cell Mol Life Sci 2007;64:1174-86.  Back to cited text no. 14
15.Jan JE, Reiter RJ, Wong PK, Bax MC, Ribary U, Wasdell MB. Melatonin has membrane receptor independent hypnotic action on neurons: A hypothesis. J Pineal Res 2011;50:233-40.  Back to cited text no. 15
16.Naguib M. Melatonin and anaesthesia: A clinical perspective. J Pineal Res 2007;42:12-21.  Back to cited text no. 16
17.Rajaratnam SMW, Arendt J. Health in the 24 hour society. Lancet 2001;358:999-1005.  Back to cited text no. 17
18.Ahmad RA, Samarkandi A, Al-Mansouri SM, Al Obeidan SA. Sedation characteristics of melatonin and midazolam for premedication of adult patients undergoing cataract surgery under local anaesthesia. Saudi J Anaesth [Serial Outline] 2007;1:6. Available from: http://www.saudija.org/text.asp?.2007/1/1/6/56264. [Last cited on 2012 Feb23].  Back to cited text no. 18
19.Wilhelmsen M, Amirian I, Reiter RJ, Rosenberg J, Gogenur I. Analgesic effects of melatonin: A review of current evidence from experimental and clinical studies. J Pineal Res 2011;51:270-7.  Back to cited text no. 19
20.Dai X, Cui SG, Li SR, Chen Q, Wang R. Melatonin attenuates the development of antinociceptive tolerance to delta but not to mu-opiod receptor agonist in mice. Behav Brain Res 2007;182:21-7.  Back to cited text no. 20
21.Li SR, Wang R, Dai X, Chen Q. Melatonin enhances antinociceptive effects of delta, but not mu-opiod agonist in mice. Brain Res 2005;1043:132-8.  Back to cited text no. 21
22.Caumo W, Torres F, Moreira NL Jr, Auzani JA, Monteiro CA, Londero G, et al.The clinical impact of pre operative melatonin on post operative outcomes in patients undergoing abdominal hysterectomy. Anesth Analg 2007;105:1263-71.  Back to cited text no. 22
23.Zahn PK, Lansmann T, Berger E, Speckmann E, Musshoff U. Gene expression and functional characterization of melatonin receptors in the spinal cord of the rat: Implications for pain modulation. J Pineal Res 2003;35:24-31.  Back to cited text no. 23
24.Ismail SA, Mowafi HA. Melatonin provides anxiolysis, enhances analgesia, decreases intraocular pressure, and promotes better operating conditions during cataract surgery under topical anaesthesia. Anesth Analg 2009;108:1146-51.  Back to cited text no. 24
25.Yu Cx, Zhu CB, Xu SF, Cao XD, Wu GC. Selective MT 2 melatonin receptor antagonist blocks melatonin-induced antinociception in rats. Neurosci Lett 2000;282:161-4.  Back to cited text no. 25
26.Chung SF, Jia WJ, Bea HB, Kim SJ, Choi JI, Kang MW, et al. Antinociceptive effects of intrathecal melatonin on formalin and thermal induced pain in rats. Korean J Pain 2006;19:137-41.  Back to cited text no. 26
27.Cardinali DP, Pagano ES, Bernasconi Pablo AS, Reynoso R, Scacchi P. Disrupted chronobiology of sleep and cytoprotection in obesity: Possible therapeutic value of melatonin. Activitas Nervosa Superior Rediviva 2011;53:159-76.  Back to cited text no. 27
28.Sutherland ER, Martin RJ, Ellison MC, Kraft M. Immunomodulatory effects of melatonin in asthma. Am J Respir Crit Care Med 2002;166:1055-61.  Back to cited text no. 28
29.Konturek SJ, Konturek PC, Brzozowski T. Melatonin in gastroprotection against stress-induced acute gastric lesions and in healing of chronic gastric ulcers. J Physiol Pharmacol 2006;57:51-66.  Back to cited text no. 29
30.Srinivasan V, Pandi-Perumal SR, Spence DW, Kato H, Cardinali DP. Melatonin in septic shock: Some recent concepts. J Crit Care 2010;25:656.e1-6.  Back to cited text no. 30
31.Reiter RJ, Garcia JJ, Pie J. Oxidative toxicity in models of neurodegeneration: Responses to melatonin. Restor Neurol Neurosci 1998;12:135-42.  Back to cited text no. 31
32.Reiter RJ, Tan DX, Fuentes-Broto L. Melatonin: A multitasking molecule. Prog Brain Res 2010;181:127-51.  Back to cited text no. 32
33.Srinivasan V, Pandi-Perumal SR, Maestroni GJ, Esquifino AI, Hardeland R, Cardinali DP. Role of melatonin in neurodegenerative diseases. Neurotox Res 2005;7:293-318.  Back to cited text no. 33
34.Kaur C, Ling EA. Anti oxidants and neuroprotection in the adult and developing central nervous system. Curr Med Chem 2008;15:3068-80.  Back to cited text no. 34
35.Sánchez-BarcelóEJ, Mediavilla MD, Reiter RJ. Clinical uses of melatonin in pediatrics. Int J Pediatr 2011;2011:892624.  Back to cited text no. 35
36.Benitez-King G, Tunez I, Bellon A, Ortiz GG, Anton-Tay F. Melatonin prevents cytoskeletal alteration and oxidative stress induced by okadaic acid in NIE-115 cells. Exp Neurol 2003;182:151-9.  Back to cited text no. 36
37.Reiter RJ. The melatonin rhythm: Both a clock and a calendar. Experientia 1993;49:654-64.  Back to cited text no. 37
38.Dawson D, Armstrong SM. Chronobiotics-drugs that shift rhythms. Pharmacol Ther 1996;69:15-36.  Back to cited text no. 38
39.Karkela J, Vakkuri O, Kaukinen S, Huang WQ, Pasanen M. The influence of anaesthesia and surgery on the circadian rhythm of melatonin. Acta Anaesthesiol Scand 2002;46:30-6.  Back to cited text no. 39
40.Sewerynek E. Melatonin and the cardiovascular system. Neuro Endocrinol Lett 2002;23:79-83.  Back to cited text no. 40
41.Buijs RM, La Fleur SE, Wortel J, Van Heyningen C, Zuiddam L, Mettenleiter TC, et al. The suprachiasmatic nucleus balances sympathetic and parasympathetic output to peripheral organs through separate preautonomic neurons. J Comp Neurol 2003;464:36-48.  Back to cited text no. 41
42.Anwar MM, Meki AR, Rahma HH. Inhibitory effects of melatonin on vascular reactivity: Possible role of vasoactive mediators. Comp Biochem Physiol C Toxicol Pharmacol 2001;130:357-67.  Back to cited text no. 42
43.Serle JB, Wang RF, Peterson WM, Plourde R, Yerxa BR. Effect of 5-MCA-NAT, a putative melatonin MT 3 receptor agonist, on intraocular pressure in glaucomatous monkeys eyes. J Glaucoma 2004;13:385-8.  Back to cited text no. 43
44.Pintor J, Pelaez J, Hoyle CH, Peral A. Ocular hypotensive effects of melatonin receptor agonists in the rabbit: Further evidence for an MT 3 receptor. Br J Pharmacol 2003;138:381-6.  Back to cited text no. 44
45.Yousaf F, Seet E, Venkatraghavan L, Abrishami A, Chung F. Efficacy and safety of melatonin as an anxiolytic and analgesic in the perioperative period: A qualitative systematic review of randomized trials. Anesthesiology 2010;113:968-76.  Back to cited text no. 45
46.Samarkandi A, Naguib M, Riad W, Thalaj A, Alotibi W, Aldammas F, et al. Melatonin vs. midazolam premedication in children: A double blind, placebo- controlled study. Eur J Anaesthesiol 2005;22:189-96.  Back to cited text no. 46
47.Naguib M, Samarkandi AH. The comparative dose-response effects of melatonin and midazolam for premedication of adult patients: A double blinded, placebo controlled study. Anesth Analg 2000;91:473-9.  Back to cited text no. 47
48.Mowafi HA, Ismail SA. Melatonin improves tourniquet tolerance and enhances post operative analgesia in patients receiving intravenous regional anaesthesia. Anesth Analg 2008;107:1422-6.  Back to cited text no. 48
49.Ionescu D, Badescu C, Ilie A, Miclutia I, Iancu C, Ion D, et al. Melatonin as pre medication for laparoscopic cholecystectomy: A double blind, placebo controlled study. Southern African Journal of Anaesthesia and Analgesia 2008;14:8-11.  Back to cited text no. 49
50.Naguib M, Samarkandi AH. Premedication with melatonin: A double blind, placebo controlled comparison with midazolam. Br J Anaesth 1999;82:875-80.  Back to cited text no. 50
51.Capuzzo M, Zanardi B, Schiffino E, Buccoliero C, Gragnaniello D, Bianchi S, et al.Melatonin does not reduce anxiety more than placebo in the elderly undergoing surgery. Anesth Analg 2006;103;121-3.  Back to cited text no. 51
52.Schimdt CM, Knief A, Deuster D, Matulat P, Zehnhoff-Dinnesen AG. Melatonin is a useful alternative to sedation in children undergoing brain stem audiometry with an age dependent success rate-a field report of 250 investigations. Neuropediatrics 2007;38:2-4.  Back to cited text no. 52
53.Johnson K, Page A, Williams H, Wassemer E, Whitehouse W. The use of melatonin as an alternative to sedation in uncooperative children undergoing an MRI examination. Clin Radiol 2002;57:502-6.  Back to cited text no. 53
54.Isik B, Baygin O, Bodur H. Premedication with melatonin versus midazolam in anxious children. Paediatr Anaesth 2008;18:636-4.  Back to cited text no. 54
55.Bajaj P. Melatonin for Anxiolysis in children. Indian J Anaesth 2009;53:504-5.  Back to cited text no. 55
  Medknow Journal  
56.Jarratt J. Perioperative melatonin use. Anaesth Intensive Care 2011;39:171-81.  Back to cited text no. 56
57.Turkistani A, Abdullah KM, Al-Shaer AA, Mazen KF, Alkatheri K. Melatonin premedication and the induction dose of propofol. Eur J Anaesthesiol 2007;24:399-402.  Back to cited text no. 57
58.Budhiraja S, Singh J. Adjuvant effects of melatonin on anaesthesia induced by thiopentone sodium, ketamine and ether in rats. Methods Find Exp Clin Pharmacol 2005;27:697-9.  Back to cited text no. 58
59.Batra YK. The future of anaesthetic pharmacology. [editorial]. Indian J Anaesth 2009;53:533-6.  Back to cited text no. 59
[PUBMED]  Medknow Journal  
60.Naguib M, Schmid PG, Baker MT. The electoencephalographic Effects of IV Anaesthetic Doses of Melatonin: Comparative studies with Thiopental and Propofol. Anesth Analg 2003;97:238-43.  Back to cited text no. 60
61.Evagelidis P, Paraskeva A, Petro-poulos G, Staikou C, Fassoulaki A. Melatonin premedication does not enhance induction of anaesthesia with sevoflurane as assessed by bispectral index monitoring. Singapore Med J 2009;50:78-81.  Back to cited text no. 61
62.Naguib M, Baker MT, Spadoni G, Gregerson M. The hypnotic and analgesic effects of 2-Bromomelatonin. Anesth Analg 2003;97:763-8.  Back to cited text no. 62
63.Rodello LF, Labanca M, Foglio E. Melatonin in dentistry. In: Watson RR, editor. Melatonin in the promotion of health, 2 nd ed. USA: Taylor and Francis Group; 2012. p. 219-31.  Back to cited text no. 63
64.Gitto E, Romeo C, Reiter RJ, Impellizzeri P, Pesce S, Basile M, et al. Melatonin reduces oxidative stress in surgical neonates. J Pediatr Surg 2004;39:184-9.  Back to cited text no. 64
65.Nickkholgh A, Schneider H, Sobirey M, Venetz WP, Hinz U, Pelzi LE, et al. The use of high dose melatonin in liver resection is safe-first clinical experience. J Pineal Res 2011;50:381-8.  Back to cited text no. 65
66.Ozcelik B, Serin IS, Basbug M, Uludag S, Narin F, Tayyar M. Effects of melatonin in the prevention of post-operative adhesion formation in a rat uterine horn adhesion model. Hum Reprod 2003;18:1703-6.  Back to cited text no. 66
67.Radwan K, Youssef M, El-Tawdy A, Zeidan M, Kamal N. Melatonin versus Gabapentin. A comparative study of preemptive medications. The Internet Journal of Anaesthesiology 2010;23 Number 1. DOI: 10.5580/265-See more at: http://www.ispub.com/journal/the-internet-journal-of-anesthesiology/volume-23-number-1/melatonin-versus-gabapentin-a-comparative-study-as- preemptive-medications.html#sthash.t GPya1v Y.dpuf.  Back to cited text no. 67
68.Borazaa H, Tuncer S, Yalcin N, Erol A, Otelcioglu S. Effects of preoperative oral melatonin premedication on postoperative analgesia, sleep quality and sedation in patients undergoing elective prostatectomy: A randomized clinical trial. JAaesth 2010;24:155-60.  Back to cited text no. 68
69.Hanania M, Kitain E. Melatonin for treatment and prevention of postoperative delirium. Anesth Analg 2002;94:338-9.  Back to cited text no. 69
70.De Jonghe A, Van Munster BC, van Oosten HE, Goslings JC, Kloen P, van Rees C, et al. The effects of melatonin versus placebo on delirium in hip fracture patients: Study protocol of a randomised, placebo-controlled, double blind trial. BMC Geriatr 2011;11:34.  Back to cited text no. 70
71.Ozcengiz D, Gunes Y, Ozmete O. Oral melatonin, dexmedetomidine and midazolam for prevention of postoperative agitation in children. J Anesth 2011;23:184-8.  Back to cited text no. 71
72.Kain ZN, Maclaren JE, Herrmann L, Mayes L, Rosenbaum A, Hata J, et al. Preoperative melatonin and its effects on induction and emergence in children undergoing anaesthesia and surgery. Anesthesiology 2009;111:44-9.  Back to cited text no. 72
73.Gogenur I, Kucukakin B, Bisgaard T, Kristiansen V, Hjortse Niels-Christian, Skene Debra J, et al. The effect of melatonin on sleep quality after laparoscopic cholecystectomy: A randomised placebo-controlled trial. Anesth Analg 2009;108:1152-6.  Back to cited text no. 73
74.Wu JY, Tsou MY, Chen TH, Chen SJ, Tsao CM, Wu CC. Therapeutic effects of melatonin on peritonitis-induced septic shock with MODS in rats. J Pineal Res 2008;45:106-16.  Back to cited text no. 74
75.Escames G, Acuna-Castroviejo D, Lopez LC, Tan DX, Maldonado MD, Sanchez-Hidalgo M, et al. Pharmacological utility of melatonin in the treatment of septic shock: Experimental and clinical evidences. J Pharm Pharmacol 2006;58:1153-65.  Back to cited text no. 75
76.Srinivasan V, Mohamed M, Koto H. Melatonin in bacterial and viral infections with focus on sepsis: A review. Recent Pat Endocr Metab Immune Drug Discov 2012;6:30-9.  Back to cited text no. 76
77.Gitto E, Karbownik M, Reiter RJ, Tan DX, Cuzzocrea S, Chiurazzi P, et al. Effects of melatonin treatment in septic newborns. Pediatr Res 2001;50:756-60.  Back to cited text no. 77
78.Bagci S, Horoz O, Yildizdas D, Reinsberg J, Bartmann P, Mueller A. Melatonin status in paediatric intensive care patients with sepsis. Pediatr Crit Care Med2012;13:e120-3.  Back to cited text no. 78
79.Maldonado MD, Murillo-Cabezas F, Calvo JR, Lardone PJ, Tan DX, Guerrero JM, et al. Crit Care Med 2007;35:1177-85.  Back to cited text no. 79
80.Karaoz E, Gultekin F, Akdogan M, Oncu M, Gokcimen A. Protective role of melatonin and a combination of vitamin C and vitamin E on lung toxicity induced by chlorpyrifos-ethyl in rats. Exp Toxicol Pathol 2002;54:97-108.  Back to cited text no. 80
81.Bourne RS, Mills GH, Minelli C. Melatonin therapy to improve nocturnal sleep in critically ill patients: Encouraging results from a small randomised controlled trial. Crit Care 2008;12:R52.  Back to cited text no. 81
82.Bourne RS, Mills GH. Melatonin: Possible implications for the post operative and critically ill patients. Intensive Care Med 2006;32:371-9.  Back to cited text no. 82
83.Citera G, Arias MA, Maldonado-Cocco JA, Lázaro MA, Rosemffet MG, Brusco LI, et al. The effect of melatonin in patients with fibromyalgia: A pilot study. Clin Rheumatol 2000;19:9-13.  Back to cited text no. 83
84.Mozaffari S, Rahimi R, Abdollahi M. Implications of melatonin therapy in irritable bowel syndrome; a systematic review. Curr Pharm Des 2010;16:3646-55.  Back to cited text no. 84
85.Claustrat B, Brun J, Geoffriau M, Zaidan R, Mallo C, Chazot G. Nocturnal plasma melatonin profile and melatonin kinetics during infusion in status migrainosus. Cephalalgia 1997;17:511-7.  Back to cited text no. 85
86.Peres MF, Zukerman E, daCunha Tanuri F, Moreira FR, Cipolla-Neto J. Melatonin 3 mg is effective for migraine prevention. Neurology 2004;63:757.  Back to cited text no. 86
87.Ambriz-Tututi M, Soto VG. Oral and spinal melatonin reduces tactile allodynia in rats via activation of MT 2 and opioid receptors. Pain 2007;132:273-80.  Back to cited text no. 87
88.Seabra ML, Bignotto M, Pinto LR, Tufik S. Randomized double blind clinical trial, controlled with placebo, of the toxicology of chronic melatonin treatment. J Pineal Res 2000;29;193-200.  Back to cited text no. 88
89.Weishaupt JH, Bartels C, Polking E, Dietrich J, Rohde G, Poeggeler B, et al. Reduced oxidative damage in ALS by high- dose enteral melatonin treatment. J Pineal Res 2006;41:313-23.  Back to cited text no. 89
90.Sugden D. Psychopharmacological effects of melatonin in mouse and rat. J Pharmacol Exp Ther 1983;227:587-91.  Back to cited text no. 90

This article has been cited by
1 Biomarkers Associated with the Outcome of Traumatic Brain Injury Patients
Leonardo Lorente
Brain Sciences. 2017; 7(11): 142
[Pubmed] | [DOI]
2 Serum melatonin levels during the first seven days of severe sepsis diagnosis are associated with sepsis severity and mortality
Leonardo Lorente,María M. Martín,Pedro Abreu-González,Antonia Pérez-Cejas,Raquel Ortiz López,José Ferreres,Jordi Solé-Violán,Lorenzo Labarta,César Díaz,Celina Llanos,Alejandro Jiménez
Enfermedades Infecciosas y Microbiología Clínica. 2017;
[Pubmed] | [DOI]
3 Agomelatine and migraine management: a successfully treated case series
Beatriz O. Plasencia-García,Samuel L. Romero-Guillena,Alicia Quirós-López,Sergio Ruiz-Doblado
Therapeutic Advances in Psychopharmacology. 2015; 5(4): 243
[Pubmed] | [DOI]
4 New Prognostic Biomarkers of Mitochondrial Oxidative Stress in Septic Patients
Leonardo Lorente
Archives of Critical Care Medicine. 2015; 1(2)
[Pubmed] | [DOI]
5 Melatonin versus midazolam premedication in children undergoing surgery: A pilot study
Eloisa Gitto,Lucia Marseglia,Gabriella DæAngelo,Sara Manti,Caterina Crisafi,Angela Simona Montalto,Pietro Impellizzeri,Russel J Reiter,Carmelo Romeo
Journal of Paediatrics and Child Health. 2015; : n/a
[Pubmed] | [DOI]
6 Serum melatonin levels are associated with mortality in severe septic patients
Leonardo Lorente,María M. Martín,Pedro Abreu-González,Thais de la Cruz,José Ferreres,Jordi Solé-Violán,Lorenzo Labarta,César Díaz,Alejandro Jiménez,Juan M. Borreguero-León
Journal of Critical Care. 2015;
[Pubmed] | [DOI]
7 Melatonin and clonidine premedication has similar impact on the pharmacokinetics and pharmacodynamics of propofol target controlled-infusions
Agnieszka Bienert,Katarzyna Wawrzyniak,Pawel Wiczling,Krzysztof Przybylowski,Zenon J. Kokot,Jan Matysiak,Agnieszka Pachutko,Martyna Józefowicz,Krzysztof Kusza,Edmund Grzeskowiak
The Journal of Clinical Pharmacology. 2014; : n/a
[Pubmed] | [DOI]


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article
    Physiological Ro...
    Potential Clinic...
   Safety of Melatonin
    Availability of ...

 Article Access Statistics
    PDF Downloaded1638    
    Comments [Add]    
    Cited by others 7    

Recommend this journal